Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Many people living with focal onset seizures (FOS) fail to achieve seizure freedom, even after taking two or more ...

Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

A novel Kv7 potassium channel opener, may offer a unique treatment option for patients with resistant focal onset seizures.

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

Biotechnology firm EpilepsyGTx has secured $33m in a Series A funding round to progress its adeno-associated viral (AAV) gene ...

Most participants with newly diagnosed focal episodes achieve seizure freedom; 27% become seizure-free with first antiseizure medications. HealthDay News — Many people with newly diagnosed focal ...

According to new research more than half of children with refractory epilepsy treated with felbamate remain on therapy for at ...

Kaylee Hill, diagnosed with epilepsy before high school, is now seizure-free after advanced mapping technology guided two successful surgeries.

NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

Emerging clinical and autopsy evidence points to late-onset epilepsy as a potentially distinct, neurodegeneration-related ...